Clinical Trial Update: Testing Trametinib as a Potential Targeted Treatment in Cancers With GNAQ or GNA11 Genetic Changes (MATCH-Subprotocol S2) [Phase 2]

View source ↗

Summary

A Phase 2 MATCH-subprotocol trial is evaluating trametinib for cancers with GNAQ or GNA11 mutations; the study is active/not recruiting and has posted results i…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lymphoma
• Multiple Myeloma
• Solid Malignant Neoplasm

Drugs mentioned

• MEKINIST (trametinib)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Advanced Lymphoma, Advanced Malignant Solid Neoplasm | Phase 2 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2023-08-04